Numerous epidemiologic studies have demonstrated that aspirin use can reduce the incidence of colorectal cancer (CRC) and colorectal adenomas, ostensibly through inhibition of COX-2 mediated progression of precursor lesions [1,2,3,4,5,6,7,8]. This evidence concerns the gene PTGS2 and colorectal carcinoma.